The previous association of IL-33 signaling-associated inflammatory biomarker with adverse cardiorenal outcomes furthermore helped to specify a precision medicine hypothesis: the clinical benefit of tozorakimab may be most pronounced in those patients with DKD who show the highest inflammatory activity.5 The gene discussed is IL33; the disease is diabetic kidney disease.